Daiwa Capital Markets lowered shares of Takeda Pharmaceutical (NYSE:TAK) from an outperform rating to a neutral rating in a research note published on Thursday morning, Briefing.com Automated Import reports.
Several other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Takeda Pharmaceutical from a buy rating to a hold rating in a research report on Wednesday, August 7th. ValuEngine lowered shares of Takeda Pharmaceutical from a hold rating to a sell rating in a research report on Wednesday, May 15th.
Shares of TAK opened at $16.72 on Thursday. The company has a market capitalization of $26.34 billion, a price-to-earnings ratio of 32.78 and a beta of 0.69. The company’s 50 day simple moving average is $17.52. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.01 and a current ratio of 1.46. Takeda Pharmaceutical has a twelve month low of $15.50 and a twelve month high of $21.95.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Further Reading: How to calculate the intrinsic value of a stock
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.